Bempegaldesleukin plus nivolumab in first-line metastatic melanoma

Source: MDLinx, July 2021

In this phase II cohort from the international, single-arm PIVOT-02 study, researchers sought to assess the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma. In total, 41 previously untreated patients with stage III/IV melanoma received BEMPEG 0.006 mg/kg plus NIVO 360 mg once every 3 weeks for ? 2 years; 38 were efficacy-evaluable (? 1 postbaseline scan).

READ THE ORIGINAL FULL ARTICLE